Logo image of VBLT

VASCULAR BIOGENICS LTD (VBLT) Stock Fundamental Analysis

NASDAQ:VBLT - Nasdaq - IL0011327454 - Common Stock - Currency: USD

0.156  -0.02 (-8.77%)

After market: 0.168 +0.01 (+7.69%)

Fundamental Rating

3

Overall VBLT gets a fundamental rating of 3 out of 10. We evaluated VBLT against 563 industry peers in the Biotechnology industry. The financial health of VBLT is average, but there are quite some concerns on its profitability. VBLT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VBLT has reported negative net income.
In the past year VBLT has reported a negative cash flow from operations.
In the past 5 years VBLT always reported negative net income.
In the past 5 years VBLT always reported negative operating cash flow.
VBLT Yearly Net Income VS EBIT VS OCF VS FCFVBLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

VBLT has a worse Return On Assets (-64.74%) than 64.62% of its industry peers.
VBLT has a Return On Equity (-82.94%) which is in line with its industry peers.
Industry RankSector Rank
ROA -64.74%
ROE -82.94%
ROIC N/A
ROA(3y)-71.09%
ROA(5y)-57.33%
ROE(3y)-93.2%
ROE(5y)-74.41%
ROIC(3y)N/A
ROIC(5y)N/A
VBLT Yearly ROA, ROE, ROICVBLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100

1.3 Margins

VBLT has a better Gross Margin (96.47%) than 97.01% of its industry peers.
VBLT's Gross Margin has declined in the last couple of years.
VBLT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.51%
GM growth 5Y-2.9%
VBLT Yearly Profit, Operating, Gross MarginsVBLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

VBLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VBLT has been increased compared to 1 year ago.
VBLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VBLT Yearly Shares OutstandingVBLT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
VBLT Yearly Total Debt VS Total AssetsVBLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

VBLT has an Altman-Z score of -16.80. This is a bad value and indicates that VBLT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.80, VBLT is doing worse than 87.54% of the companies in the same industry.
VBLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.8
ROIC/WACCN/A
WACC8.55%
VBLT Yearly LT Debt VS Equity VS FCFVBLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 4.63 indicates that VBLT has no problem at all paying its short term obligations.
VBLT has a Current ratio (4.63) which is in line with its industry peers.
A Quick Ratio of 4.63 indicates that VBLT has no problem at all paying its short term obligations.
The Quick ratio of VBLT (4.63) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.63
Quick Ratio 4.63
VBLT Yearly Current Assets VS Current LiabilitesVBLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

VBLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.41%, which is quite impressive.
VBLT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.91%.
The Revenue for VBLT have been decreasing by -45.64% on average. This is quite bad
EPS 1Y (TTM)56.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.85%
Revenue 1Y (TTM)-15.91%
Revenue growth 3Y5.52%
Revenue growth 5Y-45.64%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to decrease by -11.84% on average over the next years. This is quite bad
VBLT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.94% yearly.
EPS Next Y-15.38%
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%
EPS Next 5Y-11.84%
Revenue Next Year68.85%
Revenue Next 2Y29.94%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VBLT Yearly Revenue VS EstimatesVBLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
VBLT Yearly EPS VS EstimatesVBLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VBLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VBLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VBLT Price Earnings VS Forward Price EarningsVBLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VBLT Per share dataVBLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as VBLT's earnings are expected to decrease with -15.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VBLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VASCULAR BIOGENICS LTD

NASDAQ:VBLT (10/16/2023, 8:02:23 PM)

After market: 0.168 +0.01 (+7.69%)

0.156

-0.02 (-8.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2023-08-14/bmo
Earnings (Next)11-13 2023-11-13/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners8.48%
Ins Owner Change0%
Market Cap12.11M
Analysts45.71
Price Target5.1 (3169.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 25.18
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.01
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.74%
ROE -82.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.47%
FCFM N/A
ROA(3y)-71.09%
ROA(5y)-57.33%
ROE(3y)-93.2%
ROE(5y)-74.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.51%
GM growth 5Y-2.9%
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.68%
Cap/Sales 6.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.63
Quick Ratio 4.63
Altman-Z -16.8
F-Score5
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)65.86%
Cap/Depr(5y)79.11%
Cap/Sales(3y)106.53%
Cap/Sales(5y)142.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.85%
EPS Next Y-15.38%
EPS Next 2Y-19.29%
EPS Next 3Y-15.92%
EPS Next 5Y-11.84%
Revenue 1Y (TTM)-15.91%
Revenue growth 3Y5.52%
Revenue growth 5Y-45.64%
Sales Q2Q%-100%
Revenue Next Year68.85%
Revenue Next 2Y29.94%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.09%
OCF growth 3YN/A
OCF growth 5YN/A